JP Morgan Chase’s TG Therapeutics TGTX Stock Holding History

JP Morgan Chase’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-24,000	Closed	-$864K	–	7722
2025 Q2	$864K	Hold	24,000	–	–	﹤0.01%	4470
2025 Q1	$946K	Hold	24,000	–	–	﹤0.01%	4390
2024 Q4	$722K	Buy	+24,000	New	+$689K	﹤0.01%	4839
2022 Q4	–	Sell	-50,000	Closed	-$296K	–	6995
2022 Q3	$296K	Buy	+50,000	New	+$328K	﹤0.01%	4763
2022 Q1	–	Sell	-239,600	Closed	-$4.55M	–	7013
2021 Q4	$4.55M	Buy	+239,600	New	+$6.22M	﹤0.01%	3135
2021 Q1	–	Sell	-25,300	Closed	-$1.32M	–	6350
2020 Q4	$1.32M	Buy	+25,300	New	+$855K	﹤0.01%	3778
2019 Q2	–	Sell	-144,900	Closed	-$1.17M	–	6011
2019 Q1	$1.17M	Buy	+144,900	New	+$783K	﹤0.01%	3710

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase's TGTX Position: Q1 2026 in Review

JP Morgan Chase increased its TG Therapeutics (TGTX) stake by 14% in Q1 2026, buying an estimated $554K and bringing the position to 150,523 shares worth $4.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3360.

JP Morgan Chase first reported a position in TGTX in Q2 2013 and has held it in 45 quarters since. The position peaked at $23.2M in Q1 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

JP Morgan Chase held 150,523 shares of TG Therapeutics worth $4.74M as of Q1 2026.
JP Morgan Chase bought 18,577 TG Therapeutics shares in Q1 2026, an estimated $554K.
TG Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3360 holding.
JP Morgan Chase first reported a position in TG Therapeutics in Q2 2013 and has held it in 45 quarters since.
JP Morgan Chase's TG Therapeutics position peaked at $23.2M in Q1 2025.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.